LAMININ RECEPTOR IN BREAST TISSUE, BENIGN AND MALIGNANT TUMORS

层粘连蛋白是基底膜的一种主要糖蛋白。 某些肿瘤和正常组织表面的饱和结合 细胞。各种细胞类型(即人胰腺)的检查 癌、黑色素瘤和膀胱癌)通过活细胞 结合技术表明受体的数量为50- 每个细胞110,000，取决于细胞类型。在我们的实验室里， 从人乳腺癌中分离出层粘连蛋白受体 细胞和组织以及小鼠黑色素瘤细胞。受体和 随后的配基结合被认为是一种 在肿瘤细胞附着中的重要作用，这是 肿瘤的侵袭和转移。建议的研究是设计的 测定和关联层粘连蛋白受体结合能力 具有临床信息的乳房组织。层粘连蛋白受体 结合力在良性、恶性和 正常人的乳房组织。初步研究表明，50- 恶性肿瘤中特异性层粘连蛋白结合活性成倍增加 与良性乳腺组织的对比。这些发现表明有一个地点 可能对肿瘤侵袭顺序进行干预。

Laminin, a major glycoprotein of basement membranes, exhibits saturable binding to the surface of certain neoplastic and normal cells. Examination of various cell types (i.e. human pancreatic carcinoma, melanoma and bladder carcinoma) via live cell binding techniques indicate the number of receptors to be 50- 110,000 per cell depending on cell type. In our laboratory, the laminin receptor has been isolated from human breast carcinoma cells and tissue and mouse melanoma cells. The receptor and subsequent ligand binding have been implicated to play an important role in tumor cell attachment, one of the steps in tumor invasion and metastasis. The proposed study is designed to measure and correlate laminin receptor binding capacity of breast tissues with clinical information. Laminin receptor binding capacity markedly differs between benign, malignant and normal human breast tissue. Preliminary studies indicate a 50- fold increase in specific laminin binding activity in malignant versus benign breast tissues. These findings suggest a site for possible intervention in the sequence of tumor invasion.